Technische Universität Braunschweig

Hinweise zur

Literaturrecherche

Knut Baumann

Aufgabe

1) Erstellen einer Monographie, die in Inhalt und Struktur aktuellen Arzneibuchmonographien gleicht.
2) Erstellen eines Kommentars, der in Inhalt und Struktur einem aktuellen Arzneibuchkommentar gleicht.
3) Die Strukturformeln sollen selbst gezeichnet werden (Minimum: untersuchter Arzneistoff und Verunreinigungen; d.h. Ausnahme: ggf. komplexe Synthesen).
4) Es ist alle verwendete Literatur anzugeben. Die Literatur ist abweichend von der AB-Monographie im Monographietext als Literaturverweis anzugeben. Das Literaturverzeichnis muss die verwendeten Quellen in einheitlichem Stil zitieren.

Drugbank Strukturediteor

https://www.drugbank.ca/structures/search/small_molecule_drugs/structure



Drugbank Strukturediteor – Speichern->Image



https://doku.rz.tu-bs.de/...
...doku.php?id=software:chemdraw



Zitierstil I

Artikel (mit Titel)

1.) Buchwald, P.; Bodor, N. Computer-Aided Drug Design: The Role of Quantitative StructureProperty, Structure-Activity and Structure-Metabolism Relationships (QSPR, QSAR, QSMR). *Drugs Fut.* **2002**, *27*, 577-588.

Format: Nachname, 1. Buchstabe Vorname. (alle Autoren nennen, Autoren durch „;“ getrennt) Titel des Artikels. Zeitschrift abgekürzt (kursiv) Jahr (fett), Jahrgang (kursiv), Seiten von-bis.

Zu den Artikeln ist wenn vorhanden ein **DOI** (Digital Object Identifier anzugeben) oder ein Link in PubMed (jeder Artikel in PubMed hat eine **PMID**)

Zitierstil II

Bücher

2.) Böhm, H.-J.; Klebe, G.; Kubinyi, H. *Wirkstoffdesign*, Spektrum Akademischer Verlag: Heidelberg, 1996.

Format: Nachname, 1. Buchstabe Vorname. (alle Autoren nennen, Autoren durch „;“ getrennt) Titel des Buchs (kursiv), Name des Verlags: Verlagsort, Erscheinungsjahr.

Wenn möglich mit **DOI** o.a. **permantem Link**

Technische Universität Braunschweig

http://www.ncbi.nlm.nih.gov/pubmed/25440595



Technische Universität Braunschweig

http://www.eurekaselect.com/126427/article

Current Vascular Pharmacology
ISSN (Print): 1570-1611
ISSN (Online): 1875-6212
Epub Full Text Article
DOI: 10.2174/157016111266614112716220 9 **Price**: $95

Zeitschrift über EZB

Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists

Author(s): Jie Tang, Mu-Peng Li, Hong-Hao Zhou and Xiao-Ping Chen

Abstract:

Percutaneous coronary intervention is widely used to reduce the risk of death or cardiovascular events in patients with acute coronary syndromes. Dual antiplatelet treatm and clopidogrel has become routine practice to prevent thrombotic events after coronary surgery. Despite advances of significant reduction of thrombotic complications ir therapy, major adverse cardiovascular events still occur, suggesting the need for development of novel antiplatelet agents that act as superior alternatives to current sta Recently developed antiplatelet agents (prasugrel, ticagrelor, cangrelor and elinogrel) efficiently antagonize P2Y12 receptor, a key platelet activating signaling pathway, and aggregation induced by mediators such as ADP, collagen, thrombin and TXA2. We provide an evidence-based review on the pharmacological and clinical performance of novel antiplatelet agents that antagonize P2Y12 receptors.

http://www.ncbi.nlm.nih.gov/pubmed/23197191

Thromb Haemost. 2013 Jan;109(1):93-101 doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D[1], Komócsi A, Vorobcsuk A, Serebruany VL.

Author information

Abstract

Administration of a P2Y 12 -receptor antagonist in addition to aspirin is mandatory in patients with acute coronary syndromes (ACS) or undergoing percutaneous coronary intervention (PCI) to reduce the occurrence of thrombotic events; however, their impact on mortality and stroke is unclear. We aimed to evaluate the influence of moderate (clopidogrel) or potent (prasugrel/ticagrelor) P2Y 12 -receptor inhibition on major cardiovascular outcomes among patients with ACS or undergoing PCI. Systematic literature search was performed to find randomised, controlled clinical trials comparing the clinical impact of clopidogrel with placebo or prasugrel/ticagrelor versus clopidogrel. Outcome measures included cardiovascular death, myocardial infarction (MI), total stroke and intracranial haemorrhage (ICH). Random-effects model with Mantel-Heanszel weighting was used to pool outcomes into a meta-analysis. Four studies comparing clopidogrel with placebo and five trials comparing clopidogrel with new P2Y 12 -receptor inhibitors were identified including a total of 107.473 patients. Compared to placebo, clopidogrel reduced the risk of cardiovascular death (odds

http://th.schattauer.de/en/contents/archive/issue/1623/manuscript/19048.html

Zitierstil III

Online Ressourcen

Kurze Beschreibung und http-Adresse

4.) Prasugrel; http://www.drugbank.ca/drugs/DB06209; letzter Zugriff am 17.06.2016.

Keine Links in Datenbanken, die ein Login erfordern (SciFinder, Scopus etc.)

Allgemeine Recherche

Informationsquellen

- **Wissenschaftliche Literatur ≡ „Die Literatur“**
- Internetdatenbanken
- Arzneimittel-Hersteller (via DocCheck)
- Berufsverbände (Nds. Apothekerkammer, ABDA, …)
- Behörden (BfArM, RKI, PEI, …)
- Nachrichten (Internet)

Primärliteratur

Originalpublikationen, Basis des wissenschaftlichen Wissens

- Details
- Stark fokussiert
- Qualität: „Peer-Review-System“
- Beschaffung z.T. schwierig und teuer (PubMed und Google Scholar zeigen frei verfügbare Quellen)
- Nicht nur auf Zusammenfassung verlassen

  ⇒ Hochaktuell, detailliert

  ⇒ Kontrovers diskutierte Themen sind verstreut

Wichtige Journale

- Journal of Analytical Chemistry
- Journal of Chromatography A/B
- Journal of Pharmaceutical and Biomedical Analysis
- Analytical and Bioanalytical Chemistry
- Chromatographia
- Electrophoresis
- Analytica Chimica Acta
- Pharmaeuropa
- Journal of Medicinal Chemistry
- Bioorganic & Medicinal Chemistry
- ...u.v.m

Elektronische Zeitschriften Bibliothek

http://rzblx1.uni-regensburg.de/ezeit/search.phtml?bibid=TUBS&colors=7&lang=de

Technische Universität Braunschweig

Elektronische Zeitschriftenbibliothek



Zeitschriften
- Zeitschriftensuche
- Liste nach Fachgebiet
- Liste nach Alphabet
- Liste neuer EZB-Titel

Bibliothek
- Ansprechpartner
- Zeitschrift vorschlagen
- Bibliothek auswählen

Information & Service
- Über die EZB
- Hilfe zur EZB
- EZB-App

Zeitschriftensuche

Geben Sie bitte im folgenden Formular verschiedene Kriterien zu Ihrer gesuchten Zeitschrift ein.
Informationen über verschiedene Suchmöglichkeiten finden Sie in der Hilfe zur EZB.
Hinweis: Sie können hier nicht nach Zeitschriftenartikeln suchen.

Erweiterte Suche nach Zeitschriften

Suchkriterien

Titelwort(e) | und
ISSN | und
Verlag
Treffer pro Seite: 50

Fachgebiete einschränken

Auswahl an Fachgebieten:

- Allgemeine Sprach- und Literaturwissenschaft
- Allgemeines, Fachübergreifendes
- Anglistik. Amerikanistik
- Archäologie
- Architektur, Bauingenieur- und Vermessungswesen

Die Volltexte der Zeitschriften sind
- frei zugänglich
- für die TU Braunschweig campusweit freigeschaltet
- nur bei einem Teil der erschienenen Jahrgänge für die TU Braunschweig campusweit freigeschaltet
- nicht zugänglich(in vielen Fällen werden Abstracts angeboten)

Nutzungsbedingungen

http://rzblx1.uni-regensburg.de/ezeit/search.phtml?bibid=TUBS&colors=7&lang=de

Sekundärliteratur

I. Indexierungs- und „*Abstract*“-Dienste

II. Themenbezogene Bewertungen und Übersichtsarbeiten („Reviews“)

- Datenbanken
  - PubMed, SciFinder ($), Scopus ($), ...
- Spezielle Zeitschriften
  - Pharmacon, Pharmazie in unser Zeit, ...
  - Drugs of the Future, ...

⇒ Vorauswahl, Wertung, weniger aktuell

Tertiärliteratur

„**Das**“ etablierte Wissen in konzentrierter, strukturierter Form

- Nachschlagewerke
  - Hunnius, Pschyrembel, Hagers Handbuch, ...
  - Rote Liste, Fachinformation, ...
- Lehrbücher
  - Roth Eger Troschütz, Steinhilber et al., Mutschler, Gilman & Goodman, ...

⇒ Nachteil: zeitliche Verzögerung (5 – 10 Jahre)

Weg der Literaturrecherche



Datenbankrecherche I (PubMed o.ä.)

- Datenbankfelder: TI, AU, JN, MH, ...
- Schlagwort Vokabular: kontrolliert (MeSH) vs. unkontrolliert
  - Kontrolliertes Vokabular berücksichtigt: Schreibweise, Wortendungen, Abkürzungen, Synonyma
- Logische Operatoren (AND, OR, NOT, ggf. NEAR)
- Prioritäten „()“
  (Ibuprofen OR Paracetamol) AND Kopfschmerzen
  Ibuprofen OR (Paracetamol AND Kopfschmerzen)

Datenbankrecherche II

- Phrasen: „Morbus Crohn“
- Eingrenzungen („*Limits*“) meist unter „*Advanced Search*“
- Expandieren von Suchen
  - Kontrolliertes Vokabular: eine Ebene höher
  - Platzhalter („*“, „?“): optimi*, optimi?ed
  - Achtung: Viele Arzneistoffe enden im Englischen auf „e“, z.B. „morphine“, „methylphenidate“, …

Unterschiedliche Suchrichtung

„Rückwärtssuche“

(Zitate in Aufsatz)



Grün zitiert Grau

„Vorwärtssuche“

(Scopus, Science Citation Index)



Grau wird von Grün zitiert

Bewerten speziell wissenschaftlicher Web-Sites

- Auffinden von „*Web-Sites*“
  - Suchmaschinen
- Bewerten einer Web-Site: Im Internet kann jeder alles schreiben! Bewertung ist somit zwingend nötig!
  - Wer bietet die Information an?
  - Wer ist für den Inhalt verantwortlich?
  - Wer finanziert das Angebot?
  - Letztes Update?
  - Inhaltliche Prüfung der Information?

Recherche zur Arzneibuchmonographie I

<u>Unterpunkte des Kommentars</u>

Allgemeine Hinweise

- Andere Arzneibücher (→ BP, USP, JAP, ...)
- Ähnliche Substanzen (z.B. Lehrbücher der Pharmakologie)
- CAS-Nr. (→ SciFinder)
- Darstellung (→ SciFinder: Kategorie „Preparation“, Drugs of the Future)
- Stereochemie (→ bestimmen)
- Stabilität/Lagerung (→ SciFinder: Suchbegriff „Degradation“)
- Synonyme (→ Pharmazeutische Stoffliste, PubChem)

Recherche zur Arzneibuchmonographie II

Eigenschaften

- Aussehen
- pK_a-Wert (→ SciFinder [berechnet])
- UV, IR, ^{1}H-NMR, ^{13}C-NMR, MS (→ SciFinder; Patente)
- Löslichkeit (→ SciFinder [berechnet])

Prüfung auf Identität

- Smt, IR, UV (s. Spektren)
- Farbreaktionen (→ Roth, Eger, Troschütz)
- DC (→ Apothekengerechte Prüfvorschriften, DAC, Monographien ähnl. Substanzen)

Recherche zur Arzneibuchmonographie III

Prüfung auf Reinheit

- Optische Drehung; nachrangig: Aussehen der Lösung, pH-Wert, ...
- Verwandte Substanzen
  - Auswahl verwandter Substanzen: Synthesezwischenprodukte, Abbauprodukte
  - Suche: → SciFinder Kategorie: „Analytical Study“ hier HPLC Methoden suchen für Ausgangssubstanz und ggf. für verwandte Substanzen
- Schwermetalle (allg.; speziell wenn Metall-Katalysatoren)
- Trocknungsverlust (nachrangig)

Recherche zur Arzneibuchmonographie IV

Gehaltsbestimmung

- Auf Basis von pK_a, UV-Spektrum, HPLC-Methode

Pharmakologische Eigenschaften

- Pharmakodynamik
- Pharmakokinetik
- Indikation
- Dosierung
- Intoxikation
- Unerwünschte Wirkungen
- Kontraindikation
- ...

- Lehrbücher der Pharmakologie
- Fachinformation
- Rote Liste

Technische Universität Braunschweig

Arzneibuchmonographie

Gegeben: Indikation

Gesucht: Arzneibuchmonographie plus Kommentar zu einem Arzneistoff mit der gegebenen Indikation

Nebenbedingungen:

- Der Arzneistoff darf noch nicht in Ph. Eur., USP, BP, JP, etc. monographiert sein (vgl. PM P820 (1)-(5)) für USP)

Taktisches:

- Der Arzneistoff sollte nicht zu jung sein!

Überblick verschaffen

- Pharmazeutische Zeitung ⇒ Arzneistoffe (alphabet., Jg.)
- DrugBank
- Google Scholar
  - Schlüsselworte: HPLC, „stability indicating“, forced geradation“
- PubChem
- Wikipedia

Technische Universität Braunschweig

http://www.pharmazeutische-zeitung.de/index.php?id=46915&cId=29641

http://www.drugbank.ca/



http://www.drugbank.ca/drugs/DB06209



Link out:

- Property
- Spectra
- Synthesis
- External Links
- Similar Structures

https://pubchem.ncbi.nlm.nih.gov/

https://www.ncbi.nlm.nih.gov/pccompound?term=%22prasugrel%22



https://pubchem.ncbi.nlm.nih.gov/compound/6918456#section=Top

Compound Summary for CID 6918456 | Download | Print | Share | Help

Contents

1 2D Structure

Search | Download | Get Image



from PubChem [12]

2 3D Conformer

Search | Download

Link out:
- Property
- Literature
- Patents

https://de.wikipedia.org/wiki/Prasugrel

Benutzerkonto erstellen Anmelden

Artikel | Diskussion | Lesen | Bearbeiten | Versionsgeschichte | Suchen

WIKIPEDIA
Die freie Enzyklopädie

Hauptseite
Themenportale
Von A bis Z
Zufälliger Artikel

Mitmachen
Artikel verbessern
Neuen Artikel anlegen
Autorenportal
Hilfe
Letzte Änderungen
Kontakt
Spenden

Drucken/exportieren
Buch erstellen
Als PDF herunterladen
Druckversion

Werkzeuge
Links auf diese Seite
Änderungen an verlinkten Seiten
Spezialseiten
Permanenter Link
Seiteninformationen
Wikidata-Datenobjekt
Seite zitieren

In anderen Sprachen
English

Prasugrel

Prasugrel (Entwicklungsbezeichnungen *CS-747*, *LY640315*) ist ein Thrombozytenaggregationshemmer aus der Gruppe der Thienopyridine, der die Bildung von Blutgerinnseln (Thromben) behindert. Prasugrel ist seit 2009 zum Einsatz beim akuten Koronarsyndrom in den USA, in England, in Österreich, in der Schweiz und in Deutschland zugelassen. Es stellt damit eine Alternative zum Wirkstoff Clopidogrel aus derselben Wirkstoffgruppe dar, der derzeit noch in den meisten Fällen bei der Therapie des Herzinfarktes eingesetzt wird.

Das Arzneimittel „Efient“ (Europa) bzw. „Effient“ (USA) von Daiichi Sankyō und Eli Lilly and Company enthält als Arzneistoff Prasugrel·Hydrochlorid.

Inhaltsverzeichnis [Verbergen]

Pharmakologie [Bearbeiten]

Prasugrel ist wie die anderen Thienopyridine Clopidogrel und Ticlopidin ein Prodrug, der im Körper (durch eine Hydrolyse durch Esterasen, anschließend Oxidation durch das Cytochrom-P450-System) in den aktiven Metaboliten *R-138727* umgesetzt wird. Dies scheint schneller und zu einem größeren Anteil zu geschehen als bei den anderen Stoffen dieser Arzneistoff-Gruppe. Die Ausscheidung geschieht hauptsächlich über die Niere.

Der aktive Metabolit bindet am $P2Y_{12}$-Adenosindiphosphat-Rezeptor der Thrombozyten. In der Folge unterbleibt die Thrombozytenaktivierung über den Glykoprotein-IIb/IIIa-Rezeptorkomplex. Da die Blockierung des $P2Y_{12}$-Rezeptors irreversibel ist, bleiben die Thrombozyten während ihrer gesamten Lebensdauer beeinträchtigt. Die vollständige Gerinnungsfähigkeit des Bluts stellt sich erst mit der

Strukturformel



1:1-Gemisch aus (*R*)-Form (oben) und (*S*)-Form (unten)

Allgemeines

Freiname	Prasugrel
Andere Namen	• IUPAC: (*RS*)-[5-[2-Cyclopropyl-1-(2-fluorphenyl)- 2-oxoethyl]-6,7-dihydro-4*H*- thieno[3,2-c]pyridin-2-yl]acetat
Summenformel	$C_{20}H_{20}FNO_3S$
CAS-Nummer	• 150322-43-3 (Prasugrel) • 389574-19-0 (Prasugrel·Hydrochlorid)

Vertiefte Recherche

- SciFinder
- PubMed
- Scopus
- Google Scholar

Technische Universität Braunschweig

http://www.biblio.tu-bs.de/datenbanken/



Technische Universität Braunschweig

http://rzblx10.uni-regensburg.de/dbinfo/dbliste.php?bib_id=tubs&colors=15&ocolors=40&lett=f&gebiete=4



https://scifinder.cas.org/scifinder/login




SciFinder - Explore
SCIFINDER
A CAS SOLUTION
Preferences | SciFinder Help | Sign Out
Welcome Knut Baumann
Explore
Saved Searches
SciPlanner
REFERENCES
Research Topic
Author Name
Company Name
Document Identifier
Journal
Patent
Tags
SUBSTANCES
Chemical Structure
Markush
Molecular Formula
Property
Substance Identifier
REACTIONS
Reaction Structure
REFERENCES: RESEARCH TOPIC
Examples:
The effect of antibiotic residues on dairy products
Photocyanation of aromatic compounds
Search
Advanced Search
SAVED ANSWER SETS
2011to12
Autosaved Reference Set
View All | Import
KEEP ME POSTED
You have no profiles.
Learn how to:
Create Keep Me Posted
Contact Us | Legal
Copyright © 2016 American Chemical Society. All Rights Reserved. | 京ICP备13047075号-3


SciFinder - Explore
SCIFINDER
A CAS SOLUTION
Preferences | SciFinder Help | Sign Out
Welcome Knut Baumann
Explore
Saved Searches
SciPlanner
REFERENCES
Research Topic
Author Name
Company Name
Document Identifier
Journal
Patent
Tags
SUBSTANCES
Chemical Structure
Markush
Molecular Formula
Property
Substance Identifier
REACTIONS
Reaction Structure
Search
Advanced Search
SAVED ANSWER SETS
2011to12
Autosaved Reference Set
View All | Import
KEEP ME POSTED
You have no profiles.
Learn how to:
Create Keep Me Posted
Contact Us | Legal
Copyright © 2016 American Chemical Society. All Rights Reserved. | 京ICP备13047075号-3
https://scifinder.cas.org/scifinder/searches?type=structure


SciFinder - Explore
SCIFINDER
Preferences | SciFinder Help | Sign Out
Welcome Knut Baumann
Explore
Saved Searches
SciPlanner
REFERENCES
Research Topic
Author Name
Company Name
Document Identifier
Journal
Patent
Tags
SUBSTANCES
Chemical Structure
Markush
Molecular Formula
Property
Substance Identifier
REACTIONS
Reaction Structure
SUBSTANCES: CHEMICAL STRUCTURE
Structure Editor:
Java
Non-Java
Click to Edit
Import CXF
Search Type:
Exact Structure
Substructure
Similarity
Show precision analysis
ChemDraw
Launch a SciFinder substance or reaction search directly from ChemBioDraw Ultra 14. Learn More
Search
Advanced Search
SAVED ANSWER SETS
2011to12
Autosaved Reference Set
View All | Import
KEEP ME POSTED
You have no profiles.
Learn how to:
Create Keep Me Posted
Contact Us | Legal
Copyright © 2016 American Chemical Society. All Rights Reserved. | 京ICP备13047075号-3


SciFinder - Explore
SCIFINDER
Preferences | SciFinder Help | Sign Out
Welcome Knut Baumann
Explore
Saved Searches
SciPlanner
REFERENCES
Research Topic
Author Name
Company Name
Document Identifier
Journal
Patent
Tags
SUBSTANCES
Chemical Structure
Markush
Molecular Formula
Property
Substance Identifier
REACTIONS
Reaction Structure
SUBSTANCES: SUBSTANCE IDENTIFIER
Prasugrel
Enter one per line.
Examples:
50-00-0
999815
Acetaminophen
Search
SAVED ANSWER SETS
2011to12
Autosaved Reference Set
View All | Import
KEEP ME POSTED
You have no profiles.
Learn how to:
Create Keep Me Posted
Contact Us | Legal
Copyright © 2016 American Chemical Society. All Rights Reserved. | 京ICP备13047075号-3


SciFinder
Explore
Saved Searches
SciPlanner
Save
Print
Export
Substance Identifier "Prasugrel " > substances (1)
SUBSTANCES
Get References
Get Reactions
Get Commercial Sources
Tools
Send to SciPlanner
Analyze
Refine
Sort by: CAS Registry Number
Display Options
0 of 1 Substance Selected
1. 150322-43-3
Analyze by:
Substance Role
Analytical Study 1
Biological Study 1
Miscellaneous 1
Occurrence 1
Preparation 1
Process 1
Properties 1
Prophetic in Patents 1
Reactant or Reagent 1
Uses 1
Show More
C20 H20 F N O3 S
Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-
Key Physical Properties
Regulatory Information
Contact Us | Legal
Copyright © 2016 American Chemical Society. All Rights Reserved.


Substance Identifier "Prasugrel " > substances (1) > 150322-43-3
SUBSTANCE DETAIL
Get References
Get Reactions
Get Commercial Sources
Send to SciPlanner
Return
CAS Registry Number 150322-43-3
C20 H20 F N O3 S
Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-
Molecular Weight
373.44
Boiling Point (Predicted)
Value: 493.5±45.0 °C | Condition: Press: 760 Torr
Density (Predicted)
Value: 1.347±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
pKa (Predicted)
Value: 3.65±0.20 | Condition: Most Basic Temp: 25 °C
Other Names
2-[2-(Acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone
Thieno[3,2-c]pyridine, ethanone deriv.
2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno-[3,2-c]pyridine
2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
CS 747
View more...
Expand All | Collapse All
EXPERIMENTAL PROPERTIES
PREDICTED PROPERTIES
Biological
Chemical
Density
Lipinski
Structure Related
Thermal
Chemical Properties
Value
Condition
Note
Koc
2.17
pH 1 Temp: 25 °C
(2)



logD	2.72	pH 9 Temp: 25 °C	(2)
logD	2.72	pH 10 Temp: 25 °C	(2)
logP	2.718±0.904	Temp: 25 °C	(2)
Mass Intrinsic Solubility	Sparingly Soluble (6.3E-3 g/L)	Temp: 25 °C	(2)
Mass Solubility	Slightly Soluble (2.1 g/L)	pH 1 Temp: 25 °C	(2)
Mass Solubility	Sparingly Soluble (0.27 g/L)	pH 2 Temp: 25 °C	(2)
Mass Solubility	Sparingly Soluble (0.034 g/L)	pH 3 Temp: 25 °C	(2)
Mass Solubility	Sparingly Soluble (9.0E-3 g/L)	pH 4 Temp: 25 °C	(2)
Mass Solubility	Sparingly Soluble (6.3E-3 g/L)	pH 5 Temp: 25 °C	(2)
Mass Solubility	Sparingly Soluble (6.3E-3 g/L)	pH 6 Temp: 25 °C	(2)
Mass Solubility	Sparingly Soluble (6.3E-3 g/L)	pH 7 Temp: 25 °C	(2)
Mass Solubility	Sparingly Soluble (6.3E-3 g/L)	pH 8 Temp: 25 °C	(2)
Mass Solubility	Sparingly Soluble (6.3E-3 g/L)	pH 9 Temp: 25 °C	(2)
Mass Solubility	Sparingly Soluble (6.3E-3 g/L)	pH 10 Temp: 25 °C	(2)
Mass Solubility	Sparingly Soluble (6.3E-3 g/L)	Unbuffered Water pH 7.02 Temp: 25 °C	(2)
Molar Intrinsic Solubility	Sparingly Soluble (1.7E-5 mol/L)	Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (5.5E-3 mol/L)	pH 1 Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (7.3E-4 mol/L)	pH 2 Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (9.0E-5 mol/L)	pH 3 Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (2.4E-5 mol/L)	pH 4 Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (1.7E-5 mol/L)	pH 5 Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (1.7E-5 mol/L)	pH 6 Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (1.7E-5 mol/L)	pH 7 Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (1.7E-5 mol/L)	pH 8 Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (1.7E-5 mol/L)	pH 9 Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (1.7E-5 mol/L)	pH 10 Temp: 25 °C	(2)
Molar Solubility	Sparingly Soluble (1.7E-5 mol/L)	Unbuffered Water pH 7.02 Temp: 25 °C	(2)
Molecular Weight	373.44		(2)
pKa	3.65±0.20	Most Basic Temp: 25 °C	(2)
Vapor Pressure	7.01E-10 Torr	Temp: 25 °C	(2)

Notes

(2) Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2016 ACD/Labs)



CS 747

View more...

Expand All | Collapse All

▸ EXPERIMENTAL PROPERTIES

▾ PREDICTED PROPERTIES

Biological | Chemical | Density | Lipinski | Structure Related | Thermal

Lipinski Properties	Value	Condition	Note
Freely Rotatable Bonds	6		(2)
H Acceptors	4		(2)
H Donors	0		(2)
H Donor/Acceptor Sum	4		(2)
logP	2.718±0.904	Temp: 25 °C	(2)
Molecular Weight	373.44		(2)

Notes

(2) Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2016 ACD/Labs)

▸ PREDICTED SPECTRA

▸ REGULATORY INFORMATION

▸ BIOACTIVITY INDICATORS

▸ TARGET INDICATORS

▸ CAS REFERENCE ROLES

▸ ADDITIONAL DETAILS


PREDICTED SPECTRA
REGULATORY INFORMATION
BIOACTIVITY INDICATORS
TARGET INDICATORS
CAS REFERENCE ROLES
Roles | Patents | Nonpatents | Nonspecific Derivatives from Patents | Nonspecific Derivatives from Nonpatents
Analytical Study ✓ ✓ ✓ ✓
Biological Study ✓ ✓ ✓ ✓
Miscellaneous ✓
Occurrence ✓
Preparation ✓ ✓ ✓
Process ✓ ✓
Properties ✓ ✓ ✓
Prophetic in Patents ✓
Reactant or Reagent ✓ ✓ ✓
Uses ✓ ✓ ✓
ADDITIONAL DETAILS
Document Types
Conference, Dissertation, Journal, Patent
Source of Registration
CA
Contact Us | Legal
Copyright © 2016 American Chemical Society. All Rights Reserved. | 京ICP备13047075号-3


SciFinder
Explore
Saved Searches
SciPlanner
Save
Print
Export
Substance Identifier "Prasugrel " > substances (1) > 150322-43-3 > get references (39) > refine "English" (28)
REFERENCES
Get Substances
Get Reactions
Get Related Citations
View Only
Tools
Create Keep Me Posted Alert
Send to SciPlanner
Analyze
Refine
Categorize
Sort by: Accession Number
Display Options
0 of 28 References Selected
Analyze by:
Author Name
Magiera Sylwia 2
Vanitha Prakash K 2
Alekhya S V R 1
Alvi Shahabuddin N 1
Annapurna M Mathrusri 1
Ashutosh Kumar S 1
Baranowski Jacek 1
Bisht S P S 1
Borole T C 1
Bothara K G 1
Show More
1. Analysis of prasugrel active metabolite R-138727 in human plasma: a sensitive, highly selective and fast LC-MS/MS method
Quick View
Other Sources
By Kakarla, Sreekanth; Datla, Peda Varma; Kodali, Geetha; Seru, Ganapaty
From Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences (2016), 1020, 103-110. | Language: English, Database: CAPLUS
A cost effective, sensitive, simple, and rapid high-performance liq. chromatog.-tandem mass spectrometry method was developed and validated for the quantification of the prasugrel metabolite in human plasma. Following solid phase extn., the analyte (prasugrel active metabolite; R-138727) and internal std. (emtricitabine) were sepd. using a mobile phase in an isocratic elution mode on a reverse phase C18 column and were analyzed by an LC-MS/MS in the multiple reaction monitoring mode using the resp. [M + H]+ ions, m/z 498.3-206.0 for R-138727 and m/z 248.2-130.1 for the internal std. The assa...
2. Rapid Screening for Exposure to "Non-Target" Pharmaceuticals from Wastewater Effluents by Combining HRMS-Based Suspect Screening and Exposure Modeling
Quick View
Other Sources
By Singer, Heinz P.; Wössner, Annika E.; McArdell, Christa S.; Fenner, Kathrin
From Environmental Science & Technology (2016), Ahead of Print. | Language: English, Database: CAPLUS
Model
Analytics
Computation
LC - high resolution MS
Active pharmaceutical ingredients (APIs) have raised considerable concern over the past decade due to their widespread detection in water resources and their potential to affect ecosystem health. This triggered many attempts to prioritize the large no. of known APIs to target monitoring efforts and testing of fate and effects. However, so far, a comprehensive approach to screen for their presence in surface waters has been missing. We explore a combination of an automated suspect screening approach based on liq. chromatog. coupled to high-resoln. mass spectrometry and a model-based prioriti...
3. Chiral stationary phases and their relationship with enantiomer structures in enantioseparation research of analytical laboratory
Quick View
Other Sources
By He, Zhi-jian; Song, Hang; Zhang, Yi-wen; Wang, Dao-cai; Yao, Shun
From Journal of the Mexican Chemical Society (2015), 59(1), 43-49. | Language: English, Database: CAPLUS
Chiral stationary phases (CSPs) and mol. structure of enantiomers are two independent but related aspects in enantiosepn., which are discussed on the basis of the exptl. data from the previous study. Two enantiosepn. expts. are performed to illustrate the relationship between enantiomer structures and chiral stationary phases, one is the resoln. of mandelic acid derivs. and the other is about prasugrel. Thermodn. mechanism and theor. study with computational chem. method is helpful to understand the interactions of enantiomer and CSPs.



Aim of the present work is to develop a rapid, simple, precise, accurate and reproducible reverse phase high performance liq. chromatog. method for simultaneous detn. of Aspirin and Prasugrel in tablet dosage form. The estn. was carried out on a HIBAR (Lichrospher C-18) column with the dimensions of 250mm × 4.6mm, 5µm. Combination of Acetonitrile and 0.5% Potassium dihydrogen phosphate buffer (adjusted to pH-3 using orthophosphoric acid) in the ratio of 60:40 was used as mobile phase. The flow rate is set at 1.0ml/min and eluents were monitored at 220 nm. Both drugs were properly resolved ...

7. **Analysis of prasugrel by chromatography - review**
Quick View | Other Sources
By Housheh, Samer; Trefi, Saleh; Haroun, Mohammad; Chehna, M. Fawaz
From International Journal of Pharmaceutical Sciences Review and Research (2014), 28(2), 180-186, 7 pp.. | Language: **English**, Database: CAPLUS

A review. Prasugrel, being a potent platelet aggregation inhibitor, is used widely around the world to reduce cardiovascular risks in patients with stroke, myocardial infarction, and atherosclerosis. The aim of this review firstly to focus on a comprehensive update of chromatog. detn. of Prasugrel and its metabolites in human plasma, and in pharmaceutical prepns. It has been described using TLC, HPLC/MS, RP-HPLC, and UV methods. Secondly to localize the chromatog. conditions for sepn. and quantification. This review provides detailed information on sepn. conditions for Prasugrel alone, wi...

8. **Development and validation of stability indicating reverse-phase HPLC method for the determination of prasugrel hydrochloride and its related substances**
Quick View | Other Sources
By Reddy, K. Chandra Sekhar; Kothapalli, S. R. Pavan Kumar; Vundavilli, Jagadeesh Kumar; Sreenivas, N.; Sharma, Hemant Kumar; Mukkanti, K.
From International Journal of Pharmaceutical Sciences and Research (2014), 5(3), 919-927, 9. | Language: **English**, Database: CAPLUS

A gradient reverse-phase high performance liq. chromatog. (RP-HPLC) method has been developed and validated for the detn. of Prasugrel hydrochloride and its related substances. The well chromatog. sepn. of prasugrel from its seven related substances and degrdn. products was achieved on Sunfire C18, 5µm (250mm × 4.6mm) column temp. maintained at 45°C with a mobile phase A: 0.1% vol./vol. orthophosphoric acid in water and mobile phase B: 0.1% vol./vol. orthophosphoric acid in acetonitrile. The flow rate was 1.0mL/min, and the detection wavelength was 220nm. The developed method was validated ...

9. **Development and validation of a reverse-phase liquid chromatographic method for related substances of Prasugrel for 5 and 10 mg tablets**
Quick View | Other Sources
By Naresh Chandra Reddy, M.; Chandra Sekhar, K. B.; Kavitha, A.; Sasikiran Goud, E.
From International Journal of Pharmacy and Pharmaceutical Sciences (2014), 6(1), 90-94, 5 pp.. | Language: **English**, Database: CAPLUS

Objective: The main objective of current study was to develop and validate RP-HPLC, simple, precise, accurate and specific chromatog. method for the detn. of related substances of Prasugrel in pharmaceutical formulations. Methods: A high performance liq. chromatograph instrument and inert sustain C18, 75 × 4.6 mm, 3 µm were used for detn. of Prasugrel and its related substances. Buffer was prepd. by using 1.36 g of potassium phosphate monobasic in 1000 mL of water, adjust the pH of this soln. to 3.30 with dil. orthophosphoric acid soln. and mix well. Filter through 0.45 µm nylon filter and ...

10. **Simultaneous determination of Prasugrel and Aspirin by second order and ratio first order derivative ultraviolet spectrophotometry**
Quick View | Other Sources
By Alvi, Shahabuddin N.; Patel, Mehul N.; Kathiriya, Prakash B.; Patel, Bhavna A.; Parmar, Shraddha J.
From Journal of Spectroscopy (New York, NY, United States) (2013), 705363/1-705363/8, 8 pp.. | Language: **English**, Database: CAPLUS

Two simple, accurate, and precise UV deriv. spectrophotometric methods for the simultaneous detn. of Prasugrel and Aspirin in synthetic mixt. form were developed. The 1st method involves measurement of 2nd order deriv. spectra of Prasugrel and Aspirin. The zero crossing wavelengths 267.62 nm and 252.40 nm were selected for estn. of Prasugrel and Aspirin, resp. In the 2nd method, the 1st order derivs. of ratio spectra were calcd. and used for the detn. of Prasugrel and Aspirin by measuring the peak intensity at 268 nm and 290 nm, resp. The methods were validated as per the ICH guideline Q2 ...

11. **Comparison of different sorbent materials for solid-phase extraction of selected drugs in human urine analyzed by UHPLC-UV**
Quick View | Other Sources
By Magiera, Sylwia; Hejniak, Judyta; Baranowski, Jacek
From Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences (2014), 958, 22-28. | Language: **English**, Database: CAPLUS



A simple, rapid, cost-effective, sensitive, precise, and specific reversed phase high performance liq. chromatog. method was developed and validated for the detn. of prasugrel and aspirin in bulk and tablet dosage form. It was found that the excipient in the tablet dosage form does not interfere in the quantification of active drug by proposed method. The HPLC sepn. was carried out by reverse phase chromatog. on phenomenex C8 column(250 × 4.6 mm, 5 µ) with a mobile phase composed methanol: water 80:20 vol./vol. in isocratic mode of sepn. at flow rate 1mL/min. The detection was monitored at ...

16. **Development and validation of RP-HPLC method for the estimation of Prasugrel in bulk as well in pharmaceutical dosages form**
Quick View | Other Sources
By Ashutosh Kumar, S.; Seshagiri Rao, J. V. L. N.; Jhansi Rani, K.; Jaya Prakash, S. S. S.; Prasad, T. S. R. K. V.
From International Research Journal of Pharmacy (2013), 4(3), 254-260. | Language: **English**, Database: CAPLUS

This study was designed to develop and validate a simple, sensitive, precise, and specific reverse phase high-performance liq. chromatog. (HPLC) method for the detn. of Prasugrel in bulk and its tablet dosage forms. The HPLC sepn. was carried out by reverse phase chromatog. on XTerra column C18 (4.6 × 150 mm, 5 µm) with a mobile phase composed Potassium Dihydrogen phosphate and the pH was adjusted to 3.0 by Orthophosporic Acid & Acetonitrile in the ration of 40:60 vol./vol. in isocratic mode at a flow rate of 1.0 mL/min. The run time was maintained 5min. The detection was monitored at 210 n...

17. **Identification, synthesis and characterization of related substances of Prasugrel**
Quick View | Other Sources
By Sampath, A.; Reddy, V. Prabhakar; Goverdhan, G.; Nagaraju, G.; Reddy, P. Pratap
From Journal of Pharmaceutical Research and Opinion (2012), 2(9), 102-106. | Language: **English**, Database: CAPLUS

During the process development of Prasugrel, six related substances (impurities) ranging from 0.05 to 0.15 % were detected by a gradient high performance liq. chromatog. (HPLC) method. Liq. chromatog.-mass spectrometry (LC-MS) was performed to identify the mol. mass of these impurities. A detailed study was undertaken to characterize all the impurities. These impurities were synthesized and co-injected with sample contg. the impurities and found the retention time match of the spiked impurities. Based on the spectral data (IR, NMR and MS), these impurities were characterized as 5-[2-cyclop...

18. **Development and validation of analytical method for estimation of prasugrel Hydrochloride in bulk and in pharmaceutical formulations**
Quick View | Other Sources
By Modi, Viralkumar J.; Pingale, Prashant L.
From International Journal of Pharma and Bio Sciences (2012), 3(4), 292-298. | Language: **English**, Database: CAPLUS

A new, simple, specific, accurate, precise and rapid reverse phase high performance liq. chromatog. method was developed and validated for the detn. of prasugrel Hydrochloride in pure and tablet dosage forms. The HPLC sepn. was carried out by reverse phase chromatog. on Kromasil C18 (100 × 4.6 mm; 5µm) with a mobile phase consist of methanol buffer (600 mg potassium dihydrogen phosphate in 500 mL water, pH-2.1 adjusted with ortho phosphoric acid) in the ratio of 70:30 vol./vol. delivered in isocratic mode at a flow rate of 0.8 mL/min. The prasugrel Hydrochloride was quantified at 220 nm. Th...

19. **RP-HPLC method for simultaneous estimation of Aspirin and Prasugrel in binary combination**
Quick View | Other Sources
By Jain, Deepak Kumar; Jain, Nilesh; Verma, Jitendra
From International Journal of Pharmaceutical Sciences and Drug Research (2012), 4(3), 218-221. | Language: **English**, Database: CAPLUS

A simple, reliable, rapid, precise, sensitive, and validated RP-HPLC method was developed to det. aspirin and prasugrel in synthetic mixt. form. Chromatog. sepn. achieved isocratically on Luna C_{18} column (5µm, 150mm × 4.60mm) and acetonitrile:0.05M ammonium acetate buffer (pH 4.5) in the ratio of 75:25 (vol./vol.) as the mobile phase, at a flow rate of 0.6 mL/min. Detection was carried out at 245 nm. Parameters such as linearity, precision, accuracy, recovery, specificity and ruggedness are studied as reported in the ICH guidelines. The retention times for Aspirin and Prasugrel was found t...

20. **Development and validation of RP-HPLC method for prasugrel**
Quick View | Other Sources
By Parmar, S. J.; Patel, B. A.; Jain, A. P.
From Journal of Chemical and Pharmaceutical Research (2012), 4(7), 3373-3376. | Language: **English**, Database: CAPLUS

A reverse-phase liq. chromatog. (RP-LC) method was developed for the assay of prasugrel in bulk. The Chromatog. was performed on Kromasil C18 column. The eluted



http://dx.doi.org





S. Ashutosh Kumar et al. Int. Res. J. Pharm. 2013, 4 (3)

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

www.irjponline.com ISSN 2230 – 8407

Research Article

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF PRASUGREL IN BULK AS WELL IN PHARMACEUTICAL DOSAGES FORM

S. Ashutosh Kumar*[1], J.V.L.N.Seshagiri Rao[2], K. Jhansi Rani[1], S. S. S. Jaya Madhuri[1], T. S. R. K. V. Prasad[1]

[1]A.K.R.G College of Pharmacy, Nallajerla, West Godavari, A.P. India

[2]Pharmaceutical Analysis, Yalamarty College of Pharmacy, Tarluwada Visakhapatnam, A.P, India

Email: ashu_mpharm2007@rediffmail.com

Article Received on: 20/01/13 Revised on: 21/02/13 Approved for publication: 11/03/13

DOI: 10.7897/2230-8407.04355

IRJP is an official publication of Moksha Publishing House. Website: www.mokshaph.com

ABSTRACT

This study was designed to develop and validate a simple, sensitive, precise, and specific reverse phase high-performance liquid chromatographic (HPLC) method for the determination of Prasugrel in bulk and its tablet dosage forms. The HPLC separation was carried out by reverse phase chromatography on XTerra column C18 (4.6 x 150mm, 5 µm) with a mobile phase composed Potassium Dihydrogen phosphate and the pH has been adjusted to 3.0 by Orthophosporic Acid & Acetonitrile in the ration of 40:60 v/v in isocratic mode at a flow rate of 1.0 ml/min. The run time has been maintained 5mins. The detection was monitored at 210 nm. The Accuracy was calculated and the % Recovery was found 99.0%-101.8% and reproducibility was found to be satisfactory .The calibration curve for Prasugrel was linear from 20 to60 µg/ml. The inter-day and intra-day precision was found to be within limits. The proposed method has adequate sensitivity, reproducibility, and specificity for the determination of Prasugrel in bulk and its tablet dosage forms. The limit of detection and limit of quantification for Prasugrel were found to be 0.07 µg/ml and 0.2 µg /ml respectively. The present work was undertaken with the aim to develop and validate a rapid and consistent RP- HPLC in which the peaks will be appear with a short period of time as per ICH guideline. The proposed

Technische Universität Braunschweig



SciFinder

Explore | Saved Searches | SciPlanner | Link | Save | Print | Export

Substance Identifier "Prasugrel " > substances (1) > 150322-43-3 > get references (39) > refine "English" (28) > Comparative Study of Forced De...

REFERENCE DETAIL | Get Substances | Get Related Citations | Link to Other Sources | Send to SciPlanner

Return | Previous | Next

22. Comparative Study of Forced Degradation Behavior of Prasugrel by UPLC and HPLC and the Development of Validated Stability Indicating Assay Method

By: Sahu, Kapendra; Karthikeyan, C.; Moorthy, N. S. Hari Narayana; Trivedi, Piyush

A novel stability-indicating ultra-performance liq. chromatog. (UPLC) assay method was developed and validated for prasugrel and its degrdn. products. The UPLC sepn. was performed on Acquity UPLC BEH C_{18} column (1.7 µm, 2.1 mm × 150 mm) using isocratic mode (acetonitrile:water, 80:20 vol./vol.) at flow rate of 0.1 mL/min and the high performance liq. chromatog. (HPLC) sepn. was achieved on Phenomenex C8 column using isocratic mode (acetonitrile:10 mM ammonium acetate, 85:15 vol./vol.) at flow rate of 0.9 mL/min. Prasugrel was found to degrade significantly in hydrolytic (acid, alkali, and neutral), and oxidative stress conditions and was stable in thermal and photolytic stress conditions. The RSD (%) values calcd. for the AUC of UPLC and HPLC are 0.0039 and 0.0015, resp. The UPLC and HPLC linearity of the proposed method were investigated in the range of 10-60 µg/mL. The r^2 value of UPLC and HPLC were found to be 0.9980 and 0.9983, resp. Method detection limit (MDL) and method quantification limit (MQL) were found to be 0.20 µg/mL and 1.00 µg/mL for UPLC and 0.50 µg /mL and 1.80 µg/mL for HPLC, resp. The RSD (%) values for intra-day and inter-day precision were <1.0%, confirming that the method is sufficiently precise. The validation studies were carried out fulfilling ICH requirements.

Indexing

Pharmaceutical Analysis (Section64-3)

Concepts

Reversed-phase HPLC

RP-UPLC; stability indicating behavior detn. of prasugrel by UPLC and HPLC

Decomposition | Decomposition kinetics | Ultra-performance liquid chromatography

stability indicating behavior detn. of prasugrel by UPLC and HPLC

Substances

150322-43-3 Prasugrel

stability indicating behavior detn. of prasugrel by UPLC and HPLC

QUICK LINKS

0 Tags, 0 Comments

SOURCE

Journal of Liquid Chromatography & Related Technologies
Volume34
Issue17
Pages1870-1884
Journal; Online Computer File
2011

ISSN:1082-6076
DOI:10.1080/10826076.2011.582209

COMPANY/ORGANIZATION

School of Pharmaceutical Sciences
Rajiv Gandhi Proudyogiki Vishwavidyalaya
Bhopal, Madhya Pradesh, India 462036

ACCESSION NUMBER

2011:1299336
CAN155:599584
CAPLUS


Register | Sign in | Mobile | Librarians | Authors & Editors | Societies
Taylor & Francis Online
Access provided by Universitaet Braunschweig
Browse | Products | Open access | Shortlist | Cart
The online platform for Taylor & Francis Group content
Search
Advanced and citation search
Within current journal
Entire site
Home > List of Issues > Table Of Contents > COMPARATIVE STUDY OF FORCED DEGRADATION BEHAVIOR OF PRASUGREL BY UPLC AND HPLC AND THE DEVELOPMENT OF VALIDATED STABILITY INDICATING ASSAY METHOD
Browse journal
View all volumes and issues
Current issue
Latest articles
Most read articles
Most cited articles
Open access articles
Submit
Subscribe
About this journal
News & offers
Journal of Liquid Chromatography & Related Technologies
Volume 34, Issue 17, 2011
Select Language
Translator disclaimer
Original Articles
COMPARATIVE STUDY OF FORCED DEGRADATION BEHAVIOR OF PRASUGREL BY UPLC AND HPLC AND THE DEVELOPMENT OF VALIDATED STABILITY INDICATING ASSAY METHOD
DOI: 10.1080/10826076.2011.582209
Kapendra Sahu, C. Karthikeyan, N. S. Hari Narayana Moorthy & Piyush Trivedi
pages 1870-1884
Publishing models and article dates explained
Published online: 12 Oct 2011
Preview
Full text HTML
PDF
Access options
Alert me
Abstract
A novel stability-indicating ultra-performance liquid chromatographic (UPLC) assay method was developed and validated for prasugrel and its degradation products. The UPLC separation was performed on Acquity® UPLC BEH C18 column (1.7 µm,
Journal news
Gordon Conference Announcement
Gordon Conference Program
Sign in here
to start your access
Article metrics
Views: 220
Citations
Web of Science (3)
Scopus (7)
Article metrics information
Users also read
IDENTIFICATION OF PRASUGREL (AN ANTIPLATELET DRUG) IMPURITIES BY LC-MS/MS, RAPID DETERMINATION OF PRASUGREL HYDROCHLORIDE-RELATED SUBSTANCES, AND DEGRADATION PRODUCTS IN ACTIVE PHARMACEUTICAL INGREDIENT AND PHARMACEUTICAL DOSAGE FORMS BY STABILITY INDICATING ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD
V. Malati, et al.


Latest articles
Most read articles
Most cited articles
Open access articles
Submit
Subscribe
About this journal
News & offers
Original Articles
COMPARATIVE STUDY OF FORCED DEGRADATION BEHAVIOR OF PRASUGREL BY UPLC AND HPLC AND THE DEVELOPMENT OF VALIDATED STABILITY INDICATING ASSAY METHOD
Latest two full volumes
FREE to you for 14 days
Article metrics
Views: 220
Citations
Web of Science (3)
Scopus (7)
Article metrics information
Users also read
IDENTIFICATION OF PRASUGREL (AN ANTIPLATELET DRUG) IMPURITIES BY LC-MS/MS, RAPID DETERMINATION OF PRASUGREL HYDROCHLORIDE-RELATED SUBSTANCES, AND DEGRADATION PRODUCTS IN ACTIVE PHARMACEUTICAL INGREDIENT AND PHARMACEUTICAL DOSAGE FORMS BY STABILITY INDICATING ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD
V. Malati, et al.
Volume 36, Issue 1, 2012
A VALIDATED STABILITY INDICATING UPLC METHOD FOR SIMULTANEOUS
Sorry, you do not have access to this article.
How to gain access:
Recommend to your librarian that your institution purchase access to this publication.
Log in
If you already have an individual subscription, please log in using your Taylor & Francis Online ID to gain access.
Email Address
Password
Remember Me
Sign in
Forgot password | Register
Shibboleth | OpenAthens
Purchase options Price *
Issue Purchase EUR 285,00
Article Purchase EUR 39,00
Add to cart
*Local tax will be added as applicable
Opening up choices for today's researcher
DOI: 10.1080/10826076.2011.582209
Kapendra Sahu, C. Karthikeyan, N. S. Hari Narayana Moorthy & Piyush Trivedi
pages 1870-1884
Publishing models and article dates explained
Published online: 12 Oct 2011
Preview
Full text HTML
PDF
Access Options
Alert me

Fernleihe!



Synthese immer zuerst:
„Drugs of the Future“
Falls erfolglos, dann SciFinder




SciFinder - Reference Answ...
https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf
CAS Solutions
SCIFINDER
A CAS SOLUTION
Preferences | SciFinder Help
Sign Out
Welcome Knut Baumann
Explore
Saved Searches
SciPlanner
Save
Print
Export
Substance Identifier "Prasugrel " > substances (1) > 150322-43-3 > get references (111) > refine "English" (56)
REFERENCES
Get Substances
Get Reactions
Get Related Citations
View Only
Tools
Create Keep Me Posted Alert
Send to SciPlanner
Analyze
Refine
Categorize
Sort by: Accession Number
Display Options
0 of 56 References Selected
Page: 1 of 3
Analyze by:
Author Name
Porcs Makkay Marta 6
Mezei Tibor 5
Volk Balazs 5
Barkoczy Jozsef 4
Hajicek Josef 4
Metil Dattatray Shamrao 4
Molnar Eniko 4
Nyulasi Balint 4
Stepankova Hana 4
Gregor Tamas 3
Show More
1. Preparation of prasugrel
Quick View
PATENTPAK
By Sampath, Aalla; Metil, Dattatray Shamrao; Reddy, Jinna Rajender
From Indian Pat. Appl. (2015), IN 2013CH03945 A 20150807. | Language: English, Database: CAPLUS
The application relates to process for the prepn. of prasugrel (I) and its pharmaceutically acceptable salts. Compd. I was prepd. by alkylation of 5,6,7,7a-tetrahydrothieno[3,2-c]pyridin-2(4H)-one with 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)ethanone followed by acetylation.
2. Process for the preparation of prasugrel and pharmaceutically acceptable salts thereof
Quick View
PATENTPAK
By Patkar, Laxmikant Narhari; Mondkar, Harish Kashinath; Deshpande, Manoj Madhukarrao; Vengurlekar, Rupesh Sudhir
From Indian Pat. Appl. (2015), IN 2013MU00805 A 20150130. | Language: English, Database: CAPLUS
The invention relates to a process for the prepn. of prasugrel (I) and its pharmaceutically acceptable salts. The process for prepg. I comprising purifn. of the starting material 2-fluorobenzyl alc., 2-fluorotoluene or 2-fluorobenzyl cyanide and obtaining them substantially free from impurities is claimed. Compd. I was prepd. by bromination of 2-fluorobenzyl alc., followed by cyanation; the resulting 2-fluorobenzyl cyanide underwent purifn., followed by hydrolysis and alkylation with Et cyclopropylcarboxylate to give cyclopropyl 2-fluorobenzyl ketone, which underwent halogenation to give 2-f...
3. Improved process for the preparation of prasugrel and intermediate thereof
Quick View
PATENTPAK
By Nyulasi, Balint; Kovacs, Edina; Szabo, Eva; Pakaine Varga, Gabriella; Porcs-Makkay, Marta; Volk, Balasz; Lukacs, Gyula; Varady, Karolyne; Ruzsics, Gyorgy
From PCT Int. Appl. (2014), WO 2014114964 A2 20140731. | Language: English, Database: CAPLUS
The invention relates to an industrial scale process for the prepn. of 1-cyclopropyl-2-(2-fluorophenyl)-ethanone (I) and the use of this compd. for the prepn. of prasugrel (II). This process comprises reacting 2-fluorobenzyl chloride with magnesium followed by adding cyclopropane-carboxylic acid-dimethyl amide to thus formed the Grignard reactant (whereby the reaction is carried out in a mixt. of toluene and THF, in which mixt. the amt. of THF is 3-20 vol. %, or in methyl-tetrahydrofuran as solvent) to provide I. II was prepd. by halogenation, preferably bromination or chlorination of I foll...
O
F
(1)


SciFinder - Reference Answ...
https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf
CAS Solutions
SCIFINDER
A CAS SOLUTION
Preferences | SciFinder Help
Sign Out
Welcome Knut Baumann
Explore
Saved Searches
SciPlanner
Save
Print
Export
Substance Identifier "Prasugrel " > substances (1) > 150322-43-3 > get references (111) > refine "English" (56) > refine "Journal" (9)
REFERENCES
Get Substances
Get Reactions
Get Related Citations
View Only
Tools
Create Keep Me Posted Alert
Send to SciPlanner
Analyze
Refine
Categorize
Sort by: Accession Number
Display Options
0 of 9 References Selected
Refine by:
Research Topic
Author
Company Name
Document Type
Publication Year
Language
Database
Document Type(s)
Biography
Book
Clinical Trial
Commentary
Conference
Dissertation
Editorial
Historical
Journal
Letter
Patent
Preprint
Report
Review
Refine
1. Comparison of different sorbent materials for solid-phase extraction of selected drugs in human urine analyzed by UHPLC-UV
Quick View
Other Sources
By Magiera, Sylwia; Hejniak, Judyta; Baranowski, Jacek
From Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences (2014), 958, 22-28. | Language: English, Database: CAPLUS
A procedure based on solid-phase extn. (SPE) followed by ultra-high-performance liq. chromatog. (UHPLC) with UV detection has been developed for the anal. of multiple drugs in human urine. The compds. evaluated were aliskiren, prasugrel, rivaroxaban, prednisolone, propranolol, ketoprofen, nifedipine, naproxen, terbinafine, ibuprofen, diclofenac, sildenafil and acenocoumarol. Seventeen different solid phase extn. (SPE) cartridges were tested to evaluate their applicability for the isolation of drugs from human urine. Comparison were recovery of different drugs and reproducibility. The sampl...
2. Identification and synthesis of impurities formed during prasugrel hydrochloride preparation
Quick View
Other Sources
By Sastry, T. Umasankara; Rao, K. Nageswrara; Reddy, T. Appi; Gandhi, P.
From Asian Journal of Chemistry (2013), 25(14), 7783-7789. | Language: English, Database: CAPLUS
Synthesis and characterization of impurities formed during prepn. of prasugrel hydrochloride(I·HCl) are described. Prasugrel hydrochloride is an important platelet inhibitor used for the redn. of thrombotic cardiovascular events.
3. An improvement to the preparation of prasugrel hydrochloride
Quick View
Other Sources
By Ou, Wenhua; Yi, Weiyin; Liu, Feng; Pan, Xianhua; Peng, Xijiang
From Journal of Chemical Research (2013), 37(6), 369-371. | Language: English, Database: CAPLUS
An efficient synthesis of prasugrel, a thienopyridine ADP-receptor antagonists, is described. A thienopyridine intermediate was prepd. by N-protection, boric acid substitution and N-substitution. After acid hydrolysis of the Me ether and subsequent acetylation, prasugrel was obtained with a total yield of 50% after seven linear steps from 4,5,6,7-tetrahydrothieno [3,2-c]pyridine and 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)ethan-1-one as raw materials.
4. Identification, synthesis and characterization of related substances of Prasugrel
Quick View
Other Sources
By Sampath, A.; Reddy, V. Prabhakar; Goverdhan, G.; Nagaraju, G.; Reddy, P. Pratap
From Journal of Pharmaceutical Research and Opinion (2012), 2(9), 102-106. | Language: English, Database: CAPLUS
During the process development of Prasugrel, six related substances (impurities) ranging from 0.05 to 0.15 % were detected by a gradient high performance liq. chromatog. (HPLC) method. Liq. chromatog.-mass spectrometry (LC-MS) was performed to identify the mol. mass of these impurities. A detailed study was undertaken to

impurities. Based on the spectral data (IR, NMR and MS), these impurities were characterized as 5-[2-cyclop...

5. **Efficient synthesis of prasugrel, a novel P2Y12 receptor inhibitor**
Quick View | Other Sources
By Pan, Xianhua; Huang, Rui; Zhang, Jianshui; Ding, Liping; Li, Weijin; Zhang, Qunhui; Liu, Feng
From Tetrahedron Letters (2012), 53(40), 5364-5366. | Language: **English**, Database: CAPLUS

An efficient synthesis of prasugrel, a novel $P2Y_{12}$ receptor inhibitor, is described. The cyclopropyl-phenylethanone intermediate was prepd. by cyanide substitution, bromination, N-substitution, and the Grignard reaction. After acid hydrolysis of the Me ether and subsequent acetylation, the title product was obtained with a total yield of 21% after 10 linear steps from simple and com. available raw materials.

6. **Process Improvements of Prasugrel Hydrochloride: An Adenosine Diphosphate Receptor Antagonist**
Quick View | Other Sources
By Aalla, Sampath; Gilla, Goverdhan; Metil, Dattatray Shamrao; Anumula, Raghupathi Reddy; Vummenthala, Prabhaker Reddy; Padi, Pratap Reddy
From Organic Process Research & Development (2012), 16(2), 240-243. | Language: **English**, Database: CAPLUS



An improved process for the synthesis of prasugrel hydrochloride with an overall yield of 58%, 99.9% purity, and meeting all other quality requirements is described.

7. **Process for the preparation of 5-(2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate and salts thereof.**
Quick View | Other Sources
By Anon.
From IP.com Journal (2011), 11(6A), 29. | Language: **English**, Database: CAPLUS

The synthesis of the target compd. can be achieved by the process described herein (no data).

8. **Synthetic approaches to the 2009 new drugs**
Quick View | Other Sources
By Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin
From Bioorganic & Medicinal Chemistry (2011), 19(3), 1136-1154. | Language: **English**, Database: CAPLUS

A review. New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target. These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs. This review covers the syntheses of 21 NCEs marketed in 2009.

9. **Process for the preparation of 5-(2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate and intermediates thereof**
Quick View | Other Sources
By Anon.
From IP.com Journal (2010), 10(9B), 10. | Language: **English**, Database: CAPLUS

The tile compd. was prepd. by reaction of 2-$FC_6H_4CH_2CO_2H$ with Me(MeO)NH, treatment of the amide with cyclopropylmagnesium bromide, bromination of 2-fluorophenylacetylcyclopropane, and one-pot reaction of the bromo deriv. with 2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridine.

8. Synthetic approaches to the 2009 new drugs

By: Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin

A review. New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target. These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs. This review covers the syntheses of 21 NCEs marketed in 2009.

Indexing

Pharmacology (Section1-0)

Concepts

Molecular recognition — Synthesis

synthetic approaches to the 2009 new drugs

Substances

180064-38-4P Bonoteo

Recalbon; synthetic approaches to the 2009 new drugs

Synthetic preparation; Therapeutic use; Biological study; Preparation; Uses

65576-45-6P Saphris
110078-46-1P Mozobil
112111-43-0P Nuvigil
126784-99-4P EllaOne
129938-20-1P Priligy
138530-94-6P Dexilant
141625-93-6P Multaq
144060-53-7P Uloric
146464-95-1P Folotyn
150322-43-3P Effient



150683-30-0P Sameca

QUICK LINKS
0 Tags, 0 Comments

SOURCE
Bioorganic & Medicinal Chemistry
Volume19
Issue3
Pages1136-1154
Journal; General Review
2011
CODEN:BMECEP
ISSN:0968-0896
DOI:10.1016/j.bmc.2010.12.038

COMPANY/ORGANIZATION
Pfizer Inc.
La Jolla, CA, USA 92037

ACCESSION NUMBER
2011:136698
CAN154:350909
CAPLUS

PUBLISHER
Elsevier B.V.

LANGUAGE
English

Bioorganic & Medicinal Chemistry
Volume 19, Issue 3, 1 February 2011, Pages 1136-1154
Imaging Probes

doi:10.1016/j.bmc.2010.12.038 | How to Cite or Link Using DOI
Permissions & Reprints

Review

Synthetic approaches to the 2009 new drugs

Kevin K.-C. Liu[a, †], Subas M. Sakya[b, ‡], Christopher J. O'Donnell[b], Andrew C. Flick[b, §], Jin Li[c, ¶]

[a] Pfizer Inc., La Jolla, CA 92037, USA

[b] Pfizer Inc., Groton, CT 06340, USA

[c] Shenogen Pharma Group, Beijing, China

Received 12 November 2010; revised 15 December 2010; Accepted 16 December 2010. Available online 24 December 2010.

Abstract

New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biological target. These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the syntheses of 21 NCEs marketed in 2009.

Graphical abstract

Firefox
SciFinder - Synthetic appro... | JCPR-2011-3-4-404-409.pdf (applicati... | ScienceDirect - Bioorganic & Medicin...
www.sciencedirect.com/science/article/pii/S0968089610011296#sec18
prasugrel
Most Visited | LEO | Scholar | Rote Liste® | FachInfo | Gelbe Liste | AKdÄ | a-t | Roche | Wikipedia | SciFi | PubMed | PubChem | ChEMBL | ACS Search | Wikipedia | TU BS | EZB BS | UB BS | GBV+ | PhCh | Bookmarks

Synthesis of pralatrexate (**XVI**).

18. Prasugrel (*Effient*®)

Prasugrel is a platelet inhibitor developed by Daiichi Sankyo Co. and is marketed in the United States in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI).[72] Prasugrel was approved for use in Europe in February 2009, and is currently available in the UK. In the U.S. prasugrel is also approved for the reduction of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with PCI. Prasugrel is a member of the thienopyridine class of ADP receptor inhibitors, and irreversibly binds to P2Y12 receptors. The synthesis of prasugrel begins with the preparation of the α-ketocyclopropane **102** which is prepared as summarized in Scheme 17.[73] Conversion of 1-(bromomethyl)-2-fluorobenzene (**99**) to the corresponding Grignard reagent through reaction with magnesium followed by condensation with nitrile **100** resulted in ketone **101** in 72% yield. Chlorination of ketone **101** with $CuCl_2$ resulted in the key prasugrel coupling component **102** in 92% yield. The piperidine coupling partner was prepared by treating thiolactone **103** with TBDMSCl and triethylamine to give thiophene **104** in 91% yield. Treatment of piperidine **104** with α-chloroketone **102** resulted in enol silane **105** in 65% yield. Reaction of silylenol ether **105** with acetic anhydride in the presence of triethylamine and catalytic DMAP resulted in the preparation of prasugrel (**XVII**) in 60% yield.



Full-size image (30K)

Scheme 17.

Synthesis of prasugrel (**XVII**).

19. Saxagliptin (*Onglyza*®)

Saxagliptin, previously identified as BMS-477118, is an oral hypoglycemic of the dipeptidyl peptidase-4 (DPP-4) inhibitor class developed by Bristol-Myers Squibb for the treatment of type 2 diabetes.[74] DPP-IV is the primary enzyme responsible for degradation of incretins, such as glucagon-like peptide-1 (GLP-1), which is a hormone responsible for the glucose-dependent stimulation of insulin in humans.[75] Inhibitors of DPP-IV serve as effective glucose regulators by increasing the endogenous concentration of GLP-1. The initial discovery route to saxagliptin was a 15-step, convergent synthesis focused on the production and use of compounds **109** and **113** (Scheme 18a and Scheme 18b).[(a), 76 and [77]] While the strategy of early drug delivery involved rapid synthesis to support preclinical activities and Phase I clinical trials, as saxagliptin entered Phase II, a greater emphasis was placed on defining and demonstrating a commercially viable synthetic process. Scheme 18a describes a more expedient route to the preparation of adamantylamino acid

Synthese von Prasugrel



Technische Universität Braunschweig

Aus: Bioorg. Med. Chem. 2011, 19, 1136-1154

https://www.pubpharm.de/vufind/




FACHINFORMATIONSDIENST PHARMAZIE
TU Braunschweig
PubPharm
Deutsch
Favourites (0)
My Account
ifis
UB Braunschweig
BETA
preparation prasugrel
Structure Search
Advanced Search
Search History
Sort Relevance
1. Prasugrel Hydrochloride
in Profiles of drug substances, excipients, and related methodology | Vol. 40 (2015), p. 195-320
by Al Omari, M. | Qinna, N. | Rashid, I. | +2
Article
Get full text (direct link)
2. An improvement to the preparation of prasugrel hydrochloride
in Journal of chemical research | Vol. 37, No. 6 (2013), p. 369-371
by Ou, W. | Yi, W. | Liu, F. | +2
Article
To publication (via journal page*)
3. ChemInform Abstract: An Improvement to the Preparation of Prasugrel Hydrochloride (I).
in ChemInform | Vol. 44, No. 51 (2013), p. no
by Ou, W. | Yi, W. | Liu, F. | +2
Article
No direct access to publication possible - Send inquiry to PubPharm-Team
4. Stability-Indicating LC Method for the Determination of Prasugrel Hydrochloride in Pharmaceutical Dosage Form
in Scientia pharmaceutica | Vol. 80, No. 2 (2012), p. 379-91
by Ahirrao, V. | Patil, C. | Bembalkar, S. | +5
Electronic Article
Get full text (direct link)
5. Isolation and Structural Elucidation of an Unknown Impurity in Prasugrel by Semi-Preparative Liquid Chromatography
in Journal of chromatographic science | Vol. 53, No. 7 (2015), p. 1163-1168
by Liu, C. | Yu, Z. | Wang, F. | +7
Article
Get full text (direct link)
6. Development of novel prasugrel base microsphere-loaded tablet with enhanced stability: Physicochemical characterization and in vivo evaluation in beagle dogs
in Colloids and surfaces | Vol. 146 (2016), p. 754-761
by Kim, K. | Kim, J. | Jin, S. | +8
Article
To publication (direct link*)
7. Isolation and Structural Elucidation of an Unknown Impurity in Prasugrel by Semi-Preparative Liquid Chromatography.
in Journal of chromatographic science | Vol. 53, No. 7 (2015), p. 1163-8
by Liu, C. | Yu, Z. | Wang, F. | +7
Electronic Article
Get full text (direct link)
8. Development of novel prasugrel base microsphere-loaded tablet with enhanced stability : Physicochemical characterization and in vivo evaluation in beagle dogs
in Colloids and surfaces. B, Biointerfaces | Vol. 146 (2016), p. 754-61
by Kim, K. | Kim, J. | Jin, S. | +8
Electronic Article
To publication (direct link*)
Filter
34 Hits
Format
Articles (33)
E-Articles (19)
Printed Articles (14)
Journal Title
Journal of cardiovascular pharmacology (4)
Colloids and surfaces : an internatio... (2)
Colloids and surfaces. B, Biointerfaces (2)
more ...
Topic
Journal Article (25)
Humans (15)
G89JQ59R13 (11)
more ...
Year of Publication
From:
To:
Filter


FACHINFORMATIONSDIENST PHARMAZIE
TU Braunschweig
PubPharm
Deutsch
Favourites (0)
My Account
ifis
UB Braunschweig
BETA
preparation prasugrel
Retain currently applied filters for your next search.
Structure Search
Advanced Search
Search History
Sort Date Descending
1. Isolation and Structural Elucidation of an Unknown Impurity in Prasugrel by Semi-Preparative Liquid Chromatography
in Journal of chromatographic science | Vol. 53, No. 7 (2015), p. 1163-8
by Liu, C. | Yu, Z. | Wang, F. | +7
Electronic Article
Get full text (direct link)
*Link ermittelt, möglicherweise kein freier Zugang. (>>>Mehr Informationen)
**Kostenfreie Registrierung notwendig. (>>>Mehr Informationen)
RSS view
Save
Filter
1 Hits
Applied Filters
Journal Title: Journal of chromatographic science
Format
Articles (1)
E-Articles (1)
E-Resources (1)
Journal Title
Journal of chromatographic science
Topic
*Chromatography, High Pressure Liquid (1)
*Drug Contamination (1)
*chemistry (1)
more ...
Year of Publication
From:
To:
Filter


Firefox
Prasugrel – Wikipedia
Home - PubMed - NCBI
www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed
NCBI
Resources
How To
My NCBI
Sign In
PubMed.gov
US National Library of Medicine
National Institutes of Health
PubMed
Search
Advanced
Help
BioSystems
Books
CancerChromosomes
Conserved Domains
dbGaP
dbVar
Epigenomics
Gene
GENSAT
GEO DataSets
GEO Profiles
HomoloGene
MeSH
NCBI Web Site
NLM Catalog
OMIA
OMIM
PMC
PopSet
Probe
PubMed
PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Using PubMed
PubMed Quick Start Guide
Full Text Articles
PubMed FAQs
PubMed Tutorials
New and Noteworthy
PubMed Tools
PubMed Mobile
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Topic-Specific Queries
More Resources
MeSH Database
Journals in NCBI Databases
Clinical Trials
E-Utilities
LinkOut
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/
You are here: NCBI > Literature > PubMed
Write to the Help Desk
GETTING STARTED
NCBI Education
NCBI Help Manual
NCBI Handbook
Training & Tutorials
RESOURCES
Chemicals & Bioassays
Data & Software
DNA & RNA
Domains & Structures
Genes & Expression
Genetics & Medicine
Genomes & Maps
POPULAR
PubMed
Nucleotide
BLAST
PubMed Central
Gene
Bookshelf
Protein
FEATURED
GenBank
Reference Sequences
Map Viewer
Genome Projects
Human Genome
Mouse Genome
Influenza Virus
NCBI INFORMATION
About NCBI
Research at NCBI
NCBI Newsletter
NCBI FTP Site
NCBI on Facebook
NCBI on Twitter
NCBI on YouTube


Firefox
Prasugrel – Wikipedia
prasugrel - MeSH - NCBI
www.ncbi.nlm.nih.gov/mesh?term=prasugrel
NCBI
Resources
How To
My NCBI
Sign In
MeSH
MeSH
prasugrel
Search
Save search
Limits
Advanced
Help
Display Settings: Full
Send to:
prasugrel [Supplementary Concept]
a P2Y(12) receptor antagonist with antiplatelet activity; structure in first source
Date introduced: May 22, 2000
Registry Number: 0
Heading Mapped to:
Piperazines
Thiophenes
Entry Terms:
CS 747
CS-747
LY 640315
LY640315
LY-640315
Pharmacologic Action:
Purinergic P2Y Receptor Antagonists
PubMed search builder
Add to search builder
AND
Search PubMed
Related information
PubMed
Clinical Queries
NLM MeSH Browser
PubChem Compound
PubChem Substance
Search details
"prasugrel"[Supplementary Concept] OR prasugrel[Text Word]
Search
See more...
Recent activity
Turn Off
Clear
prasugrel (1)


Firefox
Prasugrel – Wikipedia
prasugrel [Supplementary Concept] -...
www.ncbi.nlm.nih.gov/pubmed?term=prasugrel [Supplementary Concept]
NCBI Resources How To My NCBI Sign In
PubMed.gov US National Library of Medicine National Institutes of Health
PubMed prasugrel [Supplementary Concept] Search
RSS Save search Limits Advanced Help
Display Settings: Summary, 20 per page, Sorted by Recently Added Send to:
Results: 1 to 20 of 334
<< First < Prev Page 1 of 17 Next > Last >>
1. Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
[No authors listed]
Med Lett Drugs Ther. 2011 Sep 5;53(1372):69-70.
PMID: 21897348 [PubMed - indexed for MEDLINE]
Related citations
2. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, O'Donoghue ML, Bernlochner I, Contant CF, Guo J, Sabatine MS, Schömig A, Neumann FJ, Kastrati A, Wiviott SD, Sibbing D.
Am Heart J. 2011 Sep;162(3):518-26.e5. Epub 2011 Aug 11.
PMID: 21884870 [PubMed - indexed for MEDLINE]
Related citations
3. Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Bonafede M, Jing Y, Gdovin Bergeson J, Liffmann D, Makenbaeva D, Graham J, Deitelzweig SB.
Hosp Pract (Minneap). 2011 Aug;39(3):16-22.
PMID: 21881388 [PubMed - indexed for MEDLINE]
Related citations
4. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.
Wiviott SD, Desai N, Murphy SA, Musumeci G, Ragosta M, Antman EM, Braunwald E.
Am J Cardiol. 2011 Oct 1;108(7):905-11. Epub 2011 Aug 2.
PMID: 21816379 [PubMed - indexed for MEDLINE]
Related citations
5. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes.
Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P, Rossi P, Ait-Mokhtar O, Jouve B, Collet F, Peyre JP, Wittenberg O, de Labriolle A, Camilleri E, Cheneau E, Cabassome E, Dignat-George F, Camoin-Jau L, Paganelli F.
J Am Coll Cardiol. 2011 Jul 26;58(5):467-73.
Filter your results:
All (334)
Free Full Text (63)
Review (122)
Manage Filters
Titles with your search terms
Prasugrel versus clopidogrel in patients with acute coronary syndrome [N Engl J Med. 2007]
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel wit [Lancet. 2009]
Prasugrel compared with clopidogrel in patients undergoing percutaneo [Lancet. 2009]
See more...
16 free full-text articles in PubMed Central
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resist [BMC Med. 2011]
An algorithm for use of prasugrel (effient) in patients undergoing [Crit Pathw Cardiol. 2010]
Review Prevention of the renarrowing of coronary arter [Vasc Health Risk Manag. 2010]
See all (16)...
Find related data
Database: Select
Find items


Firefox
Prasugrel – Wikipedia
prasugrel hplc - PubMed - NCBI
www.ncbi.nlm.nih.gov/pubmed?term=prasugrel hplc
NCBI Resources How To My NCBI Sign In
PubMed.gov US National Library of Medicine National Institutes of Health
PubMed prasugrel hplc Search
RSS Save search Limits Advanced Help
Display Settings: Summary, Sorted by Recently Added Send to:
Results: 5
1. Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor.
Seiler D, Doser K, Salem I.
Arzneimittelforschung. 2011;61(4):247-51.
PMID: 21650084 [PubMed - indexed for MEDLINE]
Related citations
2. The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions.
Parker RB, Laizure SC.
Drug Metab Dispos. 2010 Feb;38(2):317-22. Epub 2009 Nov 17.
PMID: 19920055 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
3. The disposition of prasugrel, a novel thienopyridine, in humans.
Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ.
Drug Metab Dispos. 2007 Jul;35(7):1096-104. Epub 2007 Apr 2.
PMID: 17403916 [PubMed - indexed for MEDLINE] Free Article
Related citations
4. Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method.
Wickremsinhe ER, Tian Y, Ruterbories KJ, Verburg EM, Weerakkody GJ, Kurihara A, Farid NA.
Drug Metab Dispos. 2007 Jun;35(6):917-21. Epub 2007 Mar 12.
PMID: 17353347 [PubMed - indexed for MEDLINE] Free Article
Related citations
5. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry.
Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, Pang H.
Rapid Commun Mass Spectrom. 2007;21(2):169-79.
Filter your results:
All (5)
Free Full Text (3)
Review (0)
Manage Filters
1 free full-text article in PubMed Central
The effect of ethanol on oral cocaine pharmacokinetics r [Drug Metab Dispos. 2010]
Find related data
Database: Select
Find items
Search details
("prasugrel"[Supplementary Concept] OR "prasugrel"[All Fields]) AND ("chromatography, high pressure liquid"[MeSH Terms] OR ("chromatography"[All Fields] AND "high"[All Fields]
Search
See more...
Recent activity
Turn Off Clear
prasugrel hplc (5)
PubMed



www.scopus.com





https://scholar.google.de/



http://online.rote-liste.de/



http://www.fachinfo.de/



http://akdae.de/